首页> 外文期刊>Medical Physics >Refinement of MLC MLC modeling improves commercial QA QA dosimetry system for SRS SRS and SBRT SBRT patient‐specific QA QA
【24h】

Refinement of MLC MLC modeling improves commercial QA QA dosimetry system for SRS SRS and SBRT SBRT patient‐specific QA QA

机译:MLC MLC模型的改进改善了SRS SRS和SBRT SBRT患者特异性QA质量的商业QA QA剂量测定系统

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose Mobius 3D (M3D) provides a volumetric dose verification of the treatment planning system's calculated dose using an independent beam model and a collapsed cone convolution superposition algorithm. However, there is a lack of investigation into M3D's accuracy and effectiveness for stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) quality assurance (QA). Here, we collaborated with the vendor to develop a revised M3D beam model for SRS/SBRT cases treated with a 6X flattening filter‐free (FFF) beam and high‐definition multiple leaf collimator (HDMLC) on an Edge linear accelerator. Methods Eighty SRS/SBRT cases, planned with AAA dose algorithm and validated with Gafchromic film, were compared to M3D dose calculations using 3D gamma analysis with 2%/2 mm gamma criteria and a 10% threshold. A revised beam model was developed by refining the HD‐MLC model in M3D to improve small field dose calculation accuracy and beam profile agreement. All cases were reanalyzed using the revised beam model. The impact of heterogeneity corrections for lung cases was investigated by applying lung density overrides to five cases. Results For the standard and revised beam models, respectively, the mean gamma passing rates were 94.6% [standard deviation (SD): 6.1%] and 98.0% [SD: 1.7%] (for the overall patient), 88.2% [SD: 17.3%] and 93.8% [SD: 6.8%] (for the brain PTV), 71.4% [SD: 18.4%] and 81.5% [SD: 14.3%] (for the lung PTV), 83.3% [SD: 16.7%] and 67.9% [SD: 23.0%] (for the spine PTV), and 78.6% [SD: 14.0%] and 86.8% [SD: 12.5%] (for the PTV of all other sites). The lung PTV mean gamma passing rates improved from 74.1% [SD: 7.5%] to 89.3% [SD: 7.2%] with the lung density overridden. The revised beam model achieved an output factor within 3% of plastic scintillator measurements for 2 × 2 cm 2 MLC field size, but larger discrepancies are still seen for smaller field sizes which necessitate further improvement of the beam model. Conclusion Special attention needs to be paid to small field dosimetry, MLC modeling, and inhomogeneity corrections in the beam model for SRS/SBRT QA. The improvements noted in this study, and further collaborations between clinical physicists and the vendor to refine the M3D beam model could enable M3D to become a premier SRS/SBRT QA tool.
机译:目的Mobius 3D(M3D)提供了使用独立光束模型和折叠锥卷积叠加算法的治疗计划系统计算剂量的体积验证。然而,缺乏对立体定向放射外科(SRS)和立体定向体放射疗法(SBR)质量保证(QA)的准确性和有效性的调查。在这里,我们与供应商合作开发用于在边缘线性加速器上用6倍扁平滤水器(FFF)梁和高清多叶子准直器(HDMLC)处理的SRS / SBRT病例的修订M3D光束模型。方法使用3Dγ分析,将80次SRS / SBRT病例与AAA剂量算法(AAA剂量算法(AAA剂量算法)进行验证,将3Dγ分析与2%/ 2mmγ标准和10%阈值进行验证。通过改进M3D中的HD-MLC模型来开发修订的光束模型,以提高小型现场剂量计算精度和光束简档协议。使用修改后的光束模型重新分析所有病例。通过将肺密度覆盖施加至五种情况,研究了肺病例对肺病例的影响。标准和修改的光束模型的结果分别是平均伽马通过率为94.6%[标准偏差(SD):6.1%]和98.0%[SD:1.7%](对于整体患者),88.2%[SD: 17.3%]和93.8%[SD:6.8%](脑PTV),71.4%[SD:18.4%]和81.5%[SD:14.3%](用于肺部PTV),83.3%[SD:16.7%] ]和67.9%[SD:23.0%](对于脊柱PTV),78.6%[SD:14.0%]和86.8%[SD:12.5%](用于所有其他网站的PTV)。肺部PTV的平均催化率从74.1%[SD:7.5%]改善为89.3%[SD:7.2%],肺密度被覆盖。修订后的光束模型在塑料闪烁体测量的3%内实现了2×2cm 2 MLC场尺寸的输出系数,但仍然可以看到较大的场尺寸差异,这需要进一步改进光束模型。结论需要对SRS / SBRT QA的梁模型中的小型现场剂量测定,MLC建模和不均匀性校正进行特别注意。本研究中注意到的改进以及临床物理学家和供应商之间的进一步合作可以使M3D光束模型能够使M3D成为Premier SRS / SBRT QA工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号